工程化造血干细胞来源小胶质细胞恢复颗粒蛋白前体可纠正颗粒蛋白前体敲除小鼠表型
该研究采用携带人GRN cDNA的慢病毒载体转导造血干细胞,移植至模拟FTD和CLN11表型的Grn-/-小鼠,比较两种启动子及静脉与脑室内给药途径,发现部分恢复小胶质样细胞产生PGRN即可纠正脂质蓄积、减少胶质增生并改善社交识别。
要点
- 在Grn-/-小鼠中,经基因矫正的HSC来源小胶质样细胞可部分恢复PGRN产生。
- 两种启动子和两种给药途径均观察到脂质蓄积纠正、胶质增生减少和社交识别改善。
- 脑室内移植使表达PGRN的细胞仅在中枢神经系统植入时也获得类似治疗效果。
核心结论
- 在中枢神经系统中持久但适度地恢复PGRN表达足以纠正Grn-/-小鼠的病理表现。
研究设计与样本
- 研究采用携带人GRN互补DNA的慢病毒载体转导造血干细胞,移植至模拟FTD和CLN11表型的Grn-/-小鼠模型。
- 比较了两种启动子:受炎症调控的HLA-DRA基因来源中低强度启动子和广泛表达的磷酸甘油酸激酶(PGK)中高强度启动子。
- 比较了静脉内和脑室内两种造血干细胞给药途径。
主要发现
- 在所有测试条件下,均观察到基因矫正的Grn-/-造血干细胞来源小胶质样细胞部分重建PGRN产生。
- 上述部分重建一致导致Grn-/-小鼠脂质蓄积纠正、胶质增生减少和社交识别改善。
- 两种启动子和两种给药途径的治疗效果相似,脑室内移植后表达PGRN的细胞及其小胶质样后代仅在中枢神经系统植入时也获得类似效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous hematopoietic stem/progenitor cell (HSC)-gene therapy (GT) represents a promising therapeutic option for progranulin (PGRN)-related neurodegenerative diseases due to mutations in the PGRN encoding gene (GRN), such as frontotemporal dementia (FTD) and neuronal ceroid lipofuscinosis 11 (CLN11). These conditions are characterized by a deficiency in PGRN, have no cure, and represent an unmet medical need. We report on the efficacy and feasibility of an HSC GT approach that used a lentiviral vector encoding the human GRN complementary DNA to transduce HSCs that then were transplanted into a Grn-/- mouse model, which mirrors both FTD and CLN11 phenotypes. Two promoters, one with medium-low strength (HLA-DRA gene-based promoter regulated by inflammation) and the other with medium-high strength [ubiquitous phosphoglycerate kinase (PGK) promoter], were compared for HSC transduction. Moreover, intravenous and intracerebroventricular HSC administration were compared. Under all tested conditions, a partial reconstitution of PGRN production by microglia-like cells (MLCs) derived from genetically corrected Grn-/- HSCs was observed, which uniformly led to a correction of lipid accumulation, reduced gliosis, and improved social recognition in Grn-/- mice. Therapeutic effects were similarly achieved with either of the promoters and administration routes and particularly also when the PGRN-expressing cells and their MLC progeny had engrafted exclusively in the central nervous system (CNS) after intracerebroventricular transplantation. These findings suggest that a durable yet modest restoration of PGRN expression in the CNS is sufficient to correct pathology.
引用
- Ciervo Y, Rigoni P, Bucciarelli L, et al. Restoration of progranulin by engineered hematopoietic stem cell-derived microglia corrects phenotypes of granulin knockout mice. Sci Transl Med. 2026. PMID: 41499526. doi:10.1126/scitranslmed.adw9930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。